Results 261 to 270 of about 547,971 (352)

Association of BMI with adherence and outcome in heart failure patients treated with wearable cardioverter defibrillator

ESC Heart Failure, Volume 12, Issue 2, Page 1295-1303, April 2025.
Abstract Background Obesity is a known risk factor for cardiovascular disease (CVD), yet an ‘obesity paradox’ has been observed in various CVD contexts. The impact of obesity on heart failure (HF) patients treated with a wearable cardioverter‐defibrillator (WCD) remains underexplored.
Mohammad Abumayyaleh, Katharina Koepsel, Julia W. Erath, Thomas Kuntz, Norbert Klein, Boldizsar Kovacs, Firat Duru, Ardan M. Saguner, Christian Blockhaus, Dong‐In Shin, Fabienne Kreimer, Michael Gotzmann, Hendrik Lapp, Thomas Beiert, Assem Aweimer, Andreas Mügge, Christel Weiß, Ibrahim El‐Battrawy, Ibrahim Akin   +18 more
wiley   +1 more source

Early Dapagliflozin in Non-diabetic Acute Myocardial Infarction Patients Post-PCI: Effects on Cardiovascular Outcomes and Left Ventricular Remodeling (EARLY DAPA-AMI). [PDF]

J Saudi Heart Assoc
Salem HSE, El-Mawardy RM, Zahran ME, Bastawy IM, Aziz MF, Attia AE.   +5 more
europepmc   +1 more source

Connecting the dots: A narrative review of the relationship between heart failure and cognitive impairment

ESC Heart Failure, Volume 12, Issue 2, Page 1119-1131, April 2025.
Abstract Large clinical data underscore that heart failure is independently associated to an increased risk of negative cognitive outcome and dementia. Emerging evidence suggests that cerebral hypoperfusion, stemming from reduced cardiac output and vascular pathology, may contribute to the largely overlapping vascular dementia and Alzheimer's disease ...
Mauro Massussi, Maria Giulia Bellicini, Marianna Adamo, Andrea Pilotto, Marco Metra, Alessandro Padovani, Riccardo Proietti   +6 more
wiley   +1 more source

The differentiation between primary aldosteronism and essential hypertension in left ventricular remodeling before and after treatment: a follow-up study with quantitative stress cardiac magnetic resonance imaging. [PDF]

Quant Imaging Med Surg
Tang L, Long Q, Yi L, Li K, Hou F, Tian L, Guo H, Cui R, Zeng M.   +8 more
europepmc   +1 more source

Sacubitril/valsartan preserves regional cardiac function following myocardial infarction in rats

ESC Heart Failure, Volume 12, Issue 2, Page 1304-1315, April 2025.
Parts of the figure were drawn by using pictures from Servier Medical Art. Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License (https://creativecommons.org/licenses/by/3.0/). Abstract Aims Sacubitril/valsartan (Sac/Val) is used for treatment of heart failure. The effect of Sac/Val on regional dysfunction
Einar Sjaastad Nordén, Bård Andre Bendiksen, Kaja Knudsen Bergo, Emil Knut Stenersen Espe, Gary McGinley, Almira Hasic, Ida Marie Hauge‐Iversen, Hege Katrin Ugland, Xin Shen, Michael Frisk, Nishani S. Mabotuwana, William E. Louch, Rizwan I. Hussain, Lili Zhang, Ivar Sjaastad, Alessandro Cataliotti, Geir Christensen   +16 more
wiley   +1 more source

Left ventricular remodeling in atrial fibrillation is associated with elevated NAP-2 and 3-nitrotyrosine. [PDF]

Biomark Med
Mołek-Dziadosz P, Natorska J, Matusik PT, Wojciechowska W, Rajzer M, Rajtar-Salwa R, Bartuś S, Surdacki A, Malinowski KP, Lenart-Migdalska A, Olszowska M, Ząbczyk M.   +11 more
europepmc   +1 more source

Left atrial function in uraemic patients: Four‐dimensional automatic left atrial quantitative technology study

ESC Heart Failure, Volume 12, Issue 2, Page 1316-1325, April 2025.
Abstract Objective This study aimed to evaluate the utility of left atrial volume and function in uraemic patients using four‐dimensional automatic left atrial quantification (4D auto LAQ) technology. Methods Thirty‐four undialysed uraemic patients (U‐ND group), 60 dialysed uraemic patients (U‐D group), and 32 healthy volunteers (N group) were enrolled
Bing Li, Meihua Chen, Xuning Huang
wiley   +1 more source

Sex-Specific Patterns and Predictors of Reverse Left Ventricular Remodeling and Outcomes in STEMI Patients with LVEF ≤ 50% After Successful Primary Angioplasty. [PDF]

Biomedicines
Buz BF, Arnautu SF, Tomescu MC, Andor M, Crisan S, Gaita D, Vacarescu C, Luca CT, Mornos C, Cozma D, Arnăutu DA.   +10 more
europepmc   +1 more source

Reframing the role of glucagon‐like peptide 1 receptor agonists in cardiovascular medicine

ESC Heart Failure, Volume 12, Issue 2, Page 923-926, April 2025.
Riccardo M. Inciardi, Alvin Chandra, Ambarish Pandey, Marco Metra   +3 more
wiley   +1 more source

Dapagliflozin alleviates high‐fat‐induced obesity cardiomyopathy by inhibiting ferroptosis

ESC Heart Failure, Volume 12, Issue 2, Page 1358-1373, April 2025.
Abstract Aim: Dapagliflozin (Dapa) is a novel hypoglycaemic agent with multiple cardiovascular protective effects, and it is widely used in treatment of heart failure patients, but whether it can improve obese phenotype of heart failure and its mechanism is still unclear.
Di Chen, Jiahao Shi, Yue Wu, Lizhu Miao, Zilin Wang, Yixuan Wang, Siwei Xu, Yu Lou   +7 more
wiley   +1 more source